The ETS family of genes are implicated in cancers such as Ewings sarcoma, acute myeloid leukemia and chronic myelomoncytic leukemia. Further, they have important functions in embryonic development. Hence, identi®ca-tion and characterization of members of this family are important. We identify a novel ETS family member, ELF3, and report its human and murine cDNA sequences. The mouse cDNA has an alternatively spliced transcript with an extra 60 bp inserted. Hence we present the organization of the murine Elf3 gene together with its exon/intron structure. This gene consists of 9 exons and 8 introns spanning 4.8 kb. ELF3 binds and transactivates ETS sequences and interestingly also shows the ability to bind a GGAT-like purine core, a preferential ETS1/ETS2 type binding site. The expression of ELF3, unlike most other ETS family members, is absent in hematopoietic cells and hematopoietic organs in humans and mice. Intriguingly, the gene is speci®cally expressed in cell lines of epithelial origin and in organs such as lung, stomach, intestine, kidney that have specialized epithelial cells. We localize the human gene to 1q32.2, a region that is ampli®ed in epithelial tumors of the breast, lung and prostate. Finally, we show that ELF3 expression is increased in a lung carcinoma and adenocarcinoma, as compared to normal tissue. ELF3 is also expressed in cell lines derived from lung cancers. These results suggest that this novel ETS gene may be involved in lung tumorigenesis.
Introduction
The ETS family of transcription factors play a role in cancer and disease (Wasylyk et al., 1993; Hromas and Klemsz, 1994) . The v-ets oncogene was originally described as a part of the gag-myb-ets fusion gene expressed by the avian retrovirus E26 (Nunn et al., 1983) . The cellular homolog of v-ets is ETS1 which is a transcription factor that binds to a GGA(A/T) core sequence in the promoters and enhancers of various cellular genes and viruses. ETS1, ETS2, ERG2 and PU-1 are proto-oncogenes which have cellular transforming and mitogenic properties when over-expressed (Seth et al., 1989; Seth and Papas, 1990; Hart et al., 1995; Moreau-Gachelin et al., 1996) . Translocations involving ETS family members are associated with cancers in humans. ERG and closely related homologue ERGB/FLI-1 have been shown to be disrupted in t(21;22) and t(11;22) chromosomal translocations, respectively, that are diagnostic of Ewings sarcomas and other primitive neuroectodermal tumors (Sorensen et al., 1994) . These translocations involve fusion of ERG/FLI1 sequences to the EWS gene (Ida et al., 1995) . ERG is also involved in t(16;21) translocations associated with acute myeloid leukemia (Shimizu et al., 1993) . ETS family member TEL is involved in t(5;12) translocations in chronic myelomonocytic leukemia (Golub et al., 1994) and t(12;21) translocations in acute lymphoblastic leukemia (Golub et al., 1995) .
The ETS family of transcription factors are conserved from Drosophila to humans. In Drosophila, ETS family members play important developmental roles: E74 plays a role in early gene regulation following ecdysone triggering (Burtis et al., 1990; Fletcher et al., 1995) ; pointed P2 and yan play critical roles in eye development (O'Neill et al., 1994) ; and D-elg plays a role in developmental programming (Schulz et al., 1993) . In humans and mice ETS proteins may function in a wide range of biological processes such as hematopoiesis (Scott et al., 1994a; Muthusamy et al., 1995) , organogenesis and branching morphogenesis (Kola et al., 1993) , and skeletal/cartilage development (Sumarsono et al., 1996) . These proteins have also been implicated in regulation of gene expression appropriate for lymphoid-function (Bhat et al., 1989 , Ho et al., 1990 Bhat and Thompson, 1990; Thomas et al., 1995) and invasive processes such as tumor metastasis and extracellular matrix degradation (Wernert et al., 1992) .
One of the most common solid tumors in humans are carcinomas which arise from the transformation of epithelial cells. Transformed breast epithelial cells have been shown to express ETS family members GABPa, PEA-3, ELF1 and ELK1 (Scott et al., 1994b) , but expression of these members is not restricted to epithelial cells. Normal epithelial organization is dependent upon speci®c cell adhesion involving Ecadherin, actin cytoskeletal-associated proteins, and integrins and the decreased expression of E-cadherin and integrins occur in breast and prostate carcinomas, and this decrease correlates with increased invasiveness (Oka et al., 1993; Zutter et al., 1993) . Epithelial tubulogenesis is responsible for the intricate organization of parenchymal organs such as the lung and mammary gland where elongation and branching of epithelial tubules is critical for organ formation (Wu and Santoro, 1996) . During development new epithelia usually arise from existing ones but mesenchymal cells are the source of new epithelial cells during organogenesis of the kidney, ovary and testis. Soluble factors produced by mesenchymal cells are thought to regulate the growth, motility and dierentiation of epithelial cells via tyrosine kinase receptors. One critical interaction appears to be between HGF (hepatocyte growth factor or scatter factor) which is produced by mesenchymal cells and the tyrosine kinase receptor c-met which is expressed predominantly on epithelial cells (Weider et al., 1996) . Co-expression of c-met and its ligand HGF in NIH3T3 ®broblasts results in the formation of tumors in nude mice with epithelial characteristics (Tsarfaty et al., 1994) . A number of studies have implicated ETS family members in the regulation of genes important in epithelial cell function including erb-B2 (Scott et al., 1994b) , c-met (Gambarotta et al., 1996) and mammary whey acidic protein (Welte et al., 1994) .
In this study we describe a new ETS family member ELF3 which is expressed in epithelial cells. The human ELF3 has been mapped to the 1q32.2 region which is frequently associated with epithelial cancers. ELF3, like other ETS family members, functions as a sequence speci®c DNA binding and transactivational factor. Further investigations may de®ne an important role for this gene in epithelial cancers of the lung, breast and prostate.
Results

Isolation of a full length human and murine ELF3/Elf3 cDNA
A cDNA fragment encoding the ETS1 DNA binding domain was used to screen the Human Genome Sciences (HGS) cDNA expressed sequence tag (EST) database. A Figure 1 Human and murine ELF3 cDNA sequences. The nucleotide sequences of (a) human ELF3 and (b) murine Elf3, and their deduced amino acid sequences (one-letter code), are shown. Numbering of the nucleotides and amino acids are indicated on the right and left respectively. The ETS DNA-binding domain is in bold. Putative AATAA polyadenylation signals are underlined as are in-frame initiation and termination codons Figure  1a ). Northern analysis of human ELF3 mRNA shows the presence of minor larger-sized transcripts ( Figure  5a ). Analysis of a larger cDNA clone from a fetal lung lambda cDNA library has established that the minor transcripts contain additional 3' untranslated sequences which result from dierential polyadenylation (data not shown).
The equivalent full-length murine cDNA was also isolated. This was achieved by screening an adult mouse lung cDNA library and by 5'-RACE. The fulllength murine cDNA is 1900 bp (Figure 1b) , which is predicted to encode a 371 amino acid protein which displays 89% identity and 93% similarity with the human amino acid sequence (Figure 2a ). Upon advice from the Genome Database (GDB) nomenclature committee, this gene was assigned the gene symbol ELF3 as of May 10 1996, the date of deposition of the localization on the GDB (Accession ID: 1230388). The human and mouse ELF3 cDNAs encode an identical putative ETS DNA-binding domain (domain C) of 80 amino acids. The ETS domain of ELF3 is moderately homologous to that of other ETS family members, with the highest amino acid identity being 49%, to Drosophila E74A (Figure 2b ). Of all of the human ETS family members, ELF3 had the highest identity with ELF1 (and NERF) within the ETS domain. However, it is interesting to note that, amongst the ETS domain sequences of various ETS family members, ELF3 is relatively divergent. The human ELF3 sequence also contains a consensus PEST domain (rich in proline, serine and threonine amino acids) and the murine amino acid sequence is highly homologous in this region (Figure 2a) . Thus, this sequence may play a role in protein stability due to protease targeting.
A computer-generated phylogenetic tree, based on ETS domain homology, suggests that ELF3 may have diverged from other ETS family members, such as ETS1 and ELF1, at a fairly early stage in the evolution of ETS genes (Figure 2c ). Perhaps signi®cantly, ELF3 also displays considerable N-terminal homology (domain A) with ETS1, ETS2, ERG2, TEL and GABPa (Figure 2d ).
Isolation of the entire murine genomic sequence
Many ETS genes are alternatively spliced to give mature mRNAs which encode protein variants. Sequencing of 5'-RACE PCR products, during the cloning of the murine cDNA, identi®ed a clone containing a 60 bp inframe insertion in the murine Elf3 cDNA sequence. This insert could arise from dierential splicing of the murine Elf3 gene. To ascertain if this insertion arose from splicing and additionally to facilitate gene targeting experiments, we isolated and sequenced the full Elf3 genomic sequence. Genomic clones were isolated from a 129SVJ genomic library. Two independent clones, l3.24 and l3.26, encompassing 30 kb of genomic sequence, span the entire Elf3 gene including 10 kb of sequence 5'-prime to the transcriptional initiation site (Figure 3a ). The 9 exons and 8 introns span 4.8 kb, with the largest intron (intron 7) only being 853 bp. Exon/intron sizes, sequences of exon/intron junctions and their genomic positions are shown in Figure 3b . All exon/intron boundaries conform to the Breatnach (GT/AG) rule (Breatnach et al., 1978) and all splice donor and acceptor sites conform to Mount's consensus sequence (Mount, 1982) . Examination of the sequence of intron II suggests that the Elf3 cDNA variant containing the extra 60 bp insertion (named Elf3b) results from the use of an alternate splice acceptor site 60 bp 5-prime of the exon 3 splice acceptor site of Elf3a (Figure 3a and b) . This additional exonic sequence is predicted to contribute 20 more amino acids to the protein encoded by Elf3b.
The site of transcriptional initiation was determined by 5'-RACE PCR. A speci®c Elf3 region was ampli®ed ( Figure 3c ) and upon sequencing of several clones containing these PCR products, a dominant transcriptional initiation site was identi®ed (Figure 3d ). This dominant transcriptional initiation site was 51 bp 3' of a consensus TATA box and 127 bp 3' of a CAAT box (Figure 3d ).
ELF3 is localized to human chromosome 1q32.2; a region implicated in epithelial cancers and encompassing the Van der Woude Syndrome (VWS) gene
We performed human chromosomal localization of ELF3 by FISH, using the ELF3 cDNA as a probe. Examination of 20 metaphases from a normal human male showed 19 metaphases with signal on one or both chromatids of chromosome 1, in the region 1q32-1q41 (76% of the signal was at 1q32.2) (Figure 4a ). There was a total of 6 non-speci®c background dots observed in these 20 metaphases. A similar result was obtained from hybridization of the probe to 15 metaphases from a second normal male (data not shown). This localization data was lodged with the GDB. The localization of ELF3 is signi®cant as it is to a region of chromosome 1 that encompasses the VWS gene, and also lies within a region implicated in breast cancer speci®cally and epithelial cancers in general (1q).
To assess if ELF3 is a candidate for the VWS gene and to obtain ®ner resolution mapping of ELF3 we carried out STS content mapping using a set of primers derived from the 3' UTR of ELF3. With these primers, a single product of the expected size (182 bp) was ampli®ed from total human DNA (Figure 4b ). The nucleotide sequence of this product was identical to the ELF3 cDNA sequence (data not shown) demonstrating that the primers were speci®c for the ELF3 locus. Three sets of genomic DNA templates were used for the STS content mapping experiments. The Coriell Mapping Panel 2 was used to verify the chromosomal assignment of ELF3 and two radiation hybrid panels, Genebridge 4 and Stanford G3, were used to re®ne the chromosomal localization. When the ELF3-speci®c primers were used in PCR reactions with the Coriell Monochromosome Panel B, a product of the correct size was ampli®ed in DNA pools A and B (Figure 4b ). The only human chromosome contained in these two pools was chromosome 1, verifying the assignment of ELF3 to chromosome 1. The same primers were used to screen the radiation hybrid panels. The ampli®cation results (data not shown) were submitted to their respective computer servers for analysis (see Materials and methods). For the Genebridge 4 Panel, the marker most tightly linked to ELF3 was WI9272 at a distance of 2.4 cR (lod score43). A more precise genetic localization can be inferred by identifying the closest anking markers, D1S412 and D1S504, which were also provided by the Radiation Hybrid Mapper server (Figure 4c ). The relative positions of these markers on chromosome 1 are 242 cM and 253 cM from the top (Dib et al., 1996) . For the Stanford G3 Panel, the marker most tightly linked to ELF3 was D1S306 at a distance of 34 cR (lod score44), which is 249 cM from the top of chromosome 1 (Dib et al., 1996) . ELF3 is therefore located 14 cM proximal to the VWS gene, and hence we have excluded ELF3 as being the gene involved in VWS. The markers found near ELF3 map to the YAC contig WC1.18 (Hudson et al., 1995) which also contains the cardiac troponin T (TNNT2) and the slow skeletal muscle troponin I (TNNI1) genes (B Schutte, manuscript in preparation). Both TNNT2 and TNNI1 map to 1q32 (Mesnard et al., 1995; Eyre et al., 1993) , and support the cytogenetic localization of ELF3 shown in Figure 4a .
Unlike most ETS family members ELF3 is not expressed in hematopoietic cells
Analysis of ELF3 expression in adult human tissues by Northern blot to poly(A) + RNA ( Figure 5a ) and in human fetal tissues by RNase protection analysis ( Figure 5b) demonstrates that ELF3 has a restricted expression pattern. Most apparent is the lack of expression in hematopoietic organs such as spleen and thymus, which are known to express many of the known ETS family of genes (Bhat et al., 1997) , and in testicular and ovarian tissues. Further, ELF3 expression was not detected in peripheral blood lymphocytes (PBLs), reinforcing the idea that expression is absent/ low in hematopoietic cells. Analysis of cell lines ( Figure  5c ) shows that ELF3 expression is absent from all but those with an epithelial origin. Lung tissue, which displays ELF3 expression contains a signi®cant proportion of specialized epithelial cells, type I and type II pneumocytes. Also ELF3 is highly expressed in fetal lung (Figure 5b ), but at lower levels in adult lung ( Figure 5a ). It is undetectable in brain and heart of a b ELF3, a novel epithelial-expressed ETS gene MJ Tymms et al fetal tissues and seen at low levels in fetal thymus ( Figure 5b ). It may be that the expression in fetal thymus is not due to lymphoid cell expression but in some other cell-type. A signi®cant number of lung cancers, adenocarcinomas and large cell carcinomas are derived from respiratory epithelium. We therefore examined ELF3 expression in some primary cancers and cell lines derived from lung cancers. Expression of ELF3 was detected in a primary large cell carcinoma and a primary adenocarcinoma, and at a higher level than in age matched normal lung (Figure 5d , lanes P1, P2 and N). ELF3 was also detected in adenocarcinoma cell line PL27 ( Analysis of Elf3 expression in murine tissues demonstrates a similar pattern to that found in human tissues ( Figure 6 ). Elf3 expression in adult mice was observed in small intestine, colon, lung, kidney and uterus, but no expression was seen in spleen, thymus, brain, heart, skeletal muscle, or ovary ( Figure 6a ). However adult murine liver displayed no Elf3 expression, whereas adult human liver displayed high ELF3 expression. Further investigation will be necessary to determine if ELF3 expression occurs in normal human liver or may have resulted from some other causes such as liver damage or cancer, especially c d Figure 2 Comparison of human and murine ELF3/Elf3 with other ETS family members. (a) Alignment of the human (H-ELF3) and murine (M-ELF3) protein sequences. Gaps, indicated by dashes, were introduced to optimize alignment. Identical amino acids are dark-shaded and similar amino acids are light-shaded. Overall, identity and similarity between the human and murine counterparts are 89 and 93%, respectively. Numbering of amino acids is shown. Domain A and domain C (ETS domain) are boxed and labeled. The region overlined by a solid bar corresponds to a putative PEST sequence. (b) Alignment and comparison of the ETS domain (domain C) of human/mouse ELF3 with other ETS family members in dierent species. ETS proteins are indicated with a species pre®x; D (Drosophila), H (human), M (mouse). Proteins examined include: E74A (Burtis et al., 1990) , ELF1 , NERF (Oettgen et al., 1996) , PEP1 , ETS4 (Chen et al., 1992) , YAN (Lai and Rubin, 1992) , TEL (Golub et al., 1994) , ELK1 (Rao et al., 1989) , ERP , SAP1 (Dalton and Treisman, 1992) , ER71 (Brown and McKnight, 1992) , ERG (Rao et al., 1987) , FLI1 (Ben-David et al., 1991) , ETS6 (Chen et al., 1992) , ETS1 (Chen, 1990) , ETS2 (Watson et al., 1988) , GABPa (LaMarco et al., 1991) , ELG , ER81 (Monte et al., 1995) , ERM (Monte et al., 1994) , PEA3 (Xin et al., 1992) , ETS3 (Chen et al., 1992) , PU1 (Klemsz et al., 1990) , and SPIB (Ray et al., 1992) . Amino acids with identity to ELF3 are shaded. Overall identity is given as a percentage. Alignments were produced with CLUSTAL W . (c) Phylogenetic tree of ETS DNA binding domains produced using maximum likelihood analysis. The alignment shown in b was analysed using the JTT-F substitution model (Jones et al., 1992) and local bootstrap values were determined for all internal branches by PROTML using R-mode search (Adachi and Hasegawa, 1996) . Only the bootstrap values for branches close to ELF3 are shown. (d) Alignment and comparison of the N-terminal sequence (domain A) of ELF3 with other ETS family members since the exact status/condition of the human RNA sample is unknown.
In the light that the organ expression patterns of some ETS genes vary during murine development from fetus to adult (Kola et al., 1993) , we examined the expression of Elf3 during embryogenesis on days 19 and 17, compared to that of the adult (Figure 6b and  c) . Essentially, the Elf3 organ expression pattern observed in the adult re¯ects that observed in fetal organs, at least at the embrogenic stages examined.
ELF3 displays sequence speci®c binding to oligonucleotides containing consensus ETS sites
The ability of ELF3 to bind speci®cally to DNA was tested by electrophoretic mobility shift assay (EMSA). ELF3 bound strongly to the E74 oligonucleotide, containing a consensus ETS binding site (Figure 7a , lane 1). Binding to E74ml, a mutant E74 oligonucleotide, was virtually undetectable (lane 2). E74ml contains a GGAA?AGAA substitution in the core of the ETS recognition site, which we and others have previously shown to obliterate the binding of ETS factors (Wasylyk et al., 1990; Nye et al., 1992; Thomas et al., 1995 Thomas et al., , 1997 . ELF3 also binds to a weaker ETS-binding site from the GM-CSF promoter (GM ± lane 4), but not to an AGAA mutant of this oligonucleotide (GMml ± lane 5). It has been suggested that a GGAT variation of the core ETS binding site is relatively selective for ETS1 and ETS2 binding, in that these proteins bind GGAT-containing sequences much more strongly than other ETS factors Bosselut et al., 1993) . Mutant E74 and GM oligonucleotides (E74m2 and GMm2 respectively) contain GGAA?GGAT substitutions. Interestingly, these still retain some binding activity for ELF3 (lanes 3 and 6 respectively). In particular, binding of ELF3 to GMm2 appears to be slightly stronger than that of the wild-type GM (lanes 4 and 6).
The ability of ELF3 to bind DNA speci®cally was con®rmed by competition experiments, in which ELF3 binding to E74 was competed by addition of excesses of unlabeled oligonucleotides (Figure 7b ). Binding of ELF3 to E74 (lane 1) was competed eciently by 100-fold and 300-fold excesses of itself (lanes 2 and 3), and by E74m2 (lanes 6 and 7). Competition by E74ml was (c) Elf3 RACE PCR ampli®cation. RACE products were analysed by agarose gel electrophoresis. The left panel (lanes 1 ± 3) has been ethidium bromide stained, and the right panel probed with Elf3 cDNA (lanes 4 ± 6). Negative controls containing the anchor primer (AP1, lanes 2 and 5) or the Elf3-speci®c primer (P1, lanes 3 and 6) are shown. A major band representing Elf3-speci®c PCR product was obtained using both primers (lanes 1 and 4, position marked by an arrow). Although other bands were seen on the EtBr stained gel (lane 1), they were not speci®c since they failed to hybridize with Elf3-speci®c probe (lane 4 (Thomas et al., 1995) . This analysis con®rmed that ETS1, but not ELF1 could bind to the GGATcore modi®ed oligonucleotide. Thus it appears that ELF3, like ETS1, is capable of binding GGAT more eectively than other ETS family members, such as ELF1, that show little or no binding to these sequences. Panel 2' with ELF3-speci®c primers. PCR products were separated by agarose gel electrophoresis, following ampli®cation with ELF3-speci®c primers using the following genomic templates: no DNA control (w), total human DNA (h), total mouse DNA (m), total hamster DNA (ha) and DNA pools of monochromosome hybrids (A ± H). Chromosomes present in pools are as follows: A (1,8,14,19,22,Y), B (1,2,9,15,20,X), C (2,3,8,10,16,21), D (3,4,9,11,14,17) , E (5,10,12,15,18,19), F (4,5,6,13,20,22), G (6,7,11,12,16,Y), H (7,13,17,18,21,X) to expression of the ETS family members ETS2 or ELF3. The CAT reporter gene driven by ®ve copies of the polyomavirus enhancer upstream of the TKminimal promoter (p5XpolyTK) had relatively higher basal expression than did pTKmin. Co-transfection with the ELF3 expression construct resulted in a further 2.5-fold transactivation of the p5XpolyTK reporter (this transactivation being statistically significant at P50.001, as compared with the basal p5XpolyTK reporter). This transcription was approximately twofold greater than that achieved with an ETS2 expression construct in these cells (Figure 8 , ETS2 transactivation is also statistically signi®cant, compared with the basal p5XpolyTK reporter, P50.01).
Discussion
ETS family transcription factors play an important role in normal cellular function and in disease. We have isolated a novel ETS gene (ELF3) from both human and mouse and additionally report the genomic organization of the murine gene. Interestingly, the mRNA expression of ELF3, unlike that of most ETS family members, was absent in hematopoietic cell lines, hematopoietic organs (such as thymus and spleen) and in peripheral blood lymphocytes. Intriguingly, ELF3 expression is only detected in cell lines of epithelial origin. Further, the gene is expressed in organs such as the lung which contain a high proportion of specialized epithelial cells. These data suggest a role for ELF3 in epithelial function. It appears, however, that not all epithelial cells express detectable levels of ELF3 mRNA, as organs such as ovary, thymus, spleen and brain have a component of specialized epithelial cells. It will be necessary to undertake detailed cellular localization studies to de®ne speci®cally the cellular distribution of ELF3. However, the ®nding that ELF3 is expressed speci®cally in cell lines of epithelial origin is signi®cant. A number of relatively ubiquitously expressed transcription factors such as AP1 (Reddy et al., 1995) and AP2 (Hennig et al., 1996) have been shown to be important in regulating transcription of epithelial genes. Only a small number of the currently described transcription factors have been shown to be restricted to epithelial cells and most of these are restricted to only a subset of specialized epithelial cells. For example, Skn-1a and Skn-1i-2, two Oct-2-related factors, are restricted to keratinocytes (Anderson et al., 1993) , TTF-1 (thyroid transcription factor-1) is a homeodomain transcription factor expressed in the thyroid, lung and parts of the brain (Ikeda et al., 1995) , and HNF-1 (hepatocyte nuclear factor-1) is a variant homeodomain protein expressed in liver (Kuo et al., 1991) . Thus, the identi®cation of an ETS family member expressed speci®cally or predominantly in epithelial cells may be relevant to normal function and to tumorigenic processes in these cells. Identification of epithelial expressed genes with cellular regulatory functions is of particular interest to the study of tumorigenesis, since the majority of solid tumors are of epithelial origin. In this context, it is also signi®cant that we have identi®ed ELF3 as being overexpressed in lung cancer cell lines and in primary lung adenocarcinomas and carcinomas.
The ELF3 gene was mapped to human chromosome 1q32 by FISH and the assignment of ELF3 to chromosome 1 was veri®ed by STS content analysis with the Coriell Mapping Panel 2. This region of chromosome 1 contains the gene responsible for Van der Woude Syndrome, a dominant craniofacial disorder. However, when the location of the ELF3 locus was re®ned with two radiation hybrid panels, it mapped between the markers D1S412 and D1S504 which are about 10 cM proximal to the Van der Woude critical region, ruling out ELF3 as a candidate for the Van der Woude Syndrome gene.
The localization of ELF3 is signi®cant, and this together with the epithelial expression pattern described in this paper and the known oncogenic properties of members of the ETS family, make ELF3 a candidate gene for involvement in epithelial cancers. Cytogenetic markers involving 1q are the most frequently observed karyotypic changes in breast cancer. Loss of heterozygosity with allelic loss of q23-q32 has been commonly observed (Chen et al., 1989) . The common region, shown to be deleted in this study, was between the renin gene and marker AT3. This is the same region identi®ed by our ELF3 localization. On the other hand, other data associates over-expression of 1q localized gene(s) with cancer. Chromosomal abnormalities in 1q are common in a wide range of solid tumors including carcinomas (Brito-Babapulle and Atkin, 1981; Douglass et al., 1985) and some leukemias (Oshimura et al., 1976) . Trisomy of 1q or a portion of 1q has been shown to be frequently present in carcinomas including breast carcinoma (Pandis et al., 1992; Ried et al., 1995) , and large bowel adenocarcinomas (Reichmann et al., 1984) . This has led to the speculation that over-expression of a gene or genes between 1q24 and 1q32 contributes to tumor progression in carcinomas (Chromosome 1 workshop 1995). 1q32 is a fragile site and translocations involving 1q32 have been shown to be associated with bladder carcinoma (Barrios et al., 1990) and ovarian cancers (Bello and Rey, 1990) and also some acute myelomonocytic leukemias (Yip et al., 1991) . Thus, it is possible to speculate, on the basis of these data, that aberant over-expression of ELF3 in human cancers may result in the transcriptional upregulation of genes important in tumor progression, especially since we have shown ELF3 over-expression in some cancers and cancer cell lines. For example ETS family members have been implicated in the transcriptional regulation of c-met (Gambarotta et al., 1996) and erb-B2 (Scott et al., 1994b) , which are expressed in epithelial cells and are thought to play a role in carcinoma tumor progression.
Protein sequence homology and conservation between various ETS family members has proven useful in identifying functional domains. For this reason, the structure of the ELF3 protein, in relation to other ETS family members, is of interest and involves the following points. Firstly, the amino acid sequence of ELF3 is quite divergent from other ETS family members, and secondly, in addition to the ETS-DNA binding domain at the C-terminal end of the protein, ELF3 shows some homology with the Nterminal region of a number of ETS members. This Nterminal domain found in a number of ETS family members has been termed the`A-domain' (Seth and Papas, 1990 ) and more recently it has been shown to be important for dimerization by TEL, and called the TEL domain (Jousset et al., 1997) . This domain may play a critical role in transactivation by specifying protein-protein interactions., Human ELF3 also has a consensus PEST sequence which is thought to be important for protein stability. Amongst the ETS family members, PU.1 also has this structural motif (Klemsz et al., 1990) , but its signi®cance in protein stability will need to be assessed. The ETS domain of ELF3 putatively involved in DNA binding shows an amino acid identity of only 32 ± 49% to a number of ETS family members ( Figure  2b ). However the critical residues shown to be important for DNA contacts in the crystal structures appear to be conserved (Donaldson et al., 1996; Kodandapani et al., 1996) . The closest ELF3 amino acid identity is observed to Drosophila E74A (49%) and human ELF1 (43%).
Using recombinant ELF3 we have shown that it binds to an ETS consensus oligonucleotide sequence containing GGAA and GGAT core nucleotides. Furthermore, we have shown that ELF3 can bind to a lower anity binding site such as that from the human GM-CSF promoter, which is ETS1 regulated in T cells. (Thomas et al., 1995; Thomas et al., 1997) The binding of ELF3 to sequences containing a GGAT core sequence may be especially signi®cant, since it has been suggested that this variation of the GGAA core may exclude or greatly reduce the binding of ETS family members other than ETS1 (Wang et al., 1992) . The ability of ETS1 to bind GGAT core sequences appears to be associated with a critical lysine residue (amino acid 388) in its DNA binding domain (Bosselut et al., 1993) , an amino acid missing in ETS family members, such as ELF1 and E74A but present in ELF3. In this study, GGAA-only core speci®city could be induced in ETS1 by mutation of this lysine. Reciprocally, GGAT-permissive binding could be provoked in ELF1 by mutation of the corresponding site to a lysine. Several ETS family members that contain the GGAT binding-associated lysine residue, similarly to ETS1, can also bind a GGAT core, but do so only in particular circumstances. Hence ELK1 can bind an ETS site with a GGAT core, but only in association with adjacently bound serum response factor (SRF) (Rao and Reddy, 1992; Treisman et al., 1992; Shore and Sharrocks, 1995) . ELK1 related SAP1 binds weakly to GGAT core binding sites, but both ELK1 and SAP1 require ACC residues¯anking one side of the core (positions 75, 74 and 73, in the ETS1 consensus) and prefer GT residues anking the other side (positions +3 and +4) to achieve binding to GGAT containing sites. It is interesting to note that these speci®c¯anking sequences, as present in the E74 oligonucleotide, confer very high anity binding for ETS1 (Nye et al., 1992; Woods et al., 1992) . FLI1 also contains the GGAT binding-associated lysine residue, but appears to bind GGAT sequences very rarely (1 in 22 binding sites tested) (Mao et al., 1994) , and again only in the context of the highest anity¯anking sequences. The situation of ETS1 binding to GGAT sequences is dierent, where a wide range of¯anking sequences are permissible (Nye et al., 1992; Woods et al., 1992) . Thus, ETS1 can bind GGAT core sequences, even when the¯anking sequences specify low anity binding, and other ETS family members appear to bind GGAT core sequences:
(1) only in the context of required¯anking sequences specifying high anity; (2) only in conjunction with other factors; or (3) not at all. In the experiments presented here, ELF3 appears to display ETS1-like binding characteristics in contrast to other ETS family members such as ELF1. Thus, on a functional basis, ELF3 could also be classi®ed in the ETS1 subfamily of ETS genes, although its DNA-binding domain sequence alone place it in the E74/ELF1 subfamily.
ETS family members containing the`A domain' (Seth and Papas, 1990 ) such as ETS1, ETS2 and ERG2 are able to transactivate reporter constructs containing multimerized Ets-binding sites from the polyoma enhancer. ELF3 is able to transactivate a polyoma-TK minimal promoter construct (Figure 8) . Even though the level of transactivation in COS cells is modest, it is statistically signi®cant and greater than that achieved by ETS2. Furthermore, at this stage no data is available on phosphorylation of ELF3 which may in¯uence transactivation. Recent data has shown that ETS1 and ETS2 require phosphorylation of a speci®c residue in the Nterminal domain by the MAP kinase pathway for full transactivational activity (Yang et al., 1996) . This phosphorylation site found in ETS1 and ETS2 is conserved with Drosophila ETS family member pointed, which plays a critical role in photoreceptor downstream of the tyrosine kinase receptor sevenless (O'Neill et al., 1994) . ELF3 does not appear to have the pointed phosphorylation domain but does contain a number of consensus phosphorylation sites for Figure 8 Transactivation by ELF3. COS cells were cotransfected with CAT reporter and transcription factor exspression constructs. Transcription of the CAT gene was driven by either pTKmin (minimal thymidine kinase promoter) or p5XpolyTK (®ve copies of the polyomavirus enhancer inserted upstream of TKmin). ETS factor expression constructs used were ETS2 (pBOSETS2) or ELF3 (pBOSELF3). In the absence of expression construct the equivalent amount of base vector (pEFBOS) was co-transfected. COS cells were processed for CAT assays and the results of at least four replicates are shown as the mean relative CAT activity with standard error of the mean (s.e.m.) bars. The mean relative CAT activity for each experiment is also given numerically. Statistically signi®cant results are indicated by asterisks. Double asterisks indicate high signi®cance (P50.01) and triple asterisks indicate extremely high signi®cance (P50.001) other protein kinases which may regulate ELF3 function.
In conclusion, this manuscript reports murine and human sequences of a novel ETS gene that is speci®cally expressed in epithelial cell lines. It maps to a region that is implicated in epithelial cancers and thus future experimentation will be aimed at studying its functional role in normal epithelial development/ function and in epithelial cancers such as lung, breast and prostate.
Materials and methods
Cell lines and culture
Monkey COS7 cells were grown in DMEM supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin, and maintained in a humidi®ed incubator at 5% CO 2 and 378C. Cell lines PL27 and L162 (Lukeis et al., 1993) were obtained from Dr S Hasthorpe (Royal Childrens Hospital, Melbourne) and maintained as for COS cells. Other cell lines were obtained from ATCC.
Plasmids
The human ETS1 cDNA, encoding the p42 isoform, was cut from pSG42 with BglII and blunt-ended with T4 polymerase. The mouse ets2 cDNA was cut from pGEM7-ME2A with BamHI and blunt-ended with T4 polymerase. The human ELF1 cDNA was cut from pSK-ELF1 (the gift of Dr J Leiden, University of Chicago, Illinois 60637, USA) with EcoRI and XhoI, and blunt-ended with T4 polymerase. ETS1, ETS2, ELF1 and ELF3 cDNAs were ligated into XbaI cut, T4 polymerase blunted, pEFBOS mammalian expression vector (Mizushima and Nagata, 1990) , to give pBOS-ETS1, pBOS-ETS2, pBOS-ELF1 and pBOS-ELF3, respectively. pX5polyTK was made by cloning multimerized polyoma enhancer oligonucleotides into the BamHI site of pBLCAT2. pHis6-ELF3 expression vector was made as follows: The human ELF3 cDNA was ampli®ed using PCR oligonucleotide primers (5'-CGGGATCCGCTGCAAC-CTGTGAGATTAGC-3' and 5'-GCAGATCTCAGTTCC-GACTCTGGAGAACC-3') containing a BamHI restriction site which encodes codon 2 followed by 21 nucleotides of the human ELF3 coding sequence and a BglII restriction site followed by 21 nucleotides complementary to the last 22 nucleotides of the ELF3 coding sequence. The BamHI ± BglII restriction fragment was cloned into the BamHI site of the pQE-30 (Qiagen, Inc. Chatsworth, CA) bacterial expression vector resulting in a N-terminal fusion of ELF3 protein to six histidine residues (His-Tag).
Electrophoretic mobility shift assays (EMSA)
Puri®ed recombinant ELF3 protein was produced in E. coli using pHis6-ELF3. An overnight culture was diluted 1/10 in LB broth and grown for 1 h at 378C. Recombinant protein expression was induced by addition of 0.1 mM IPTG and culture of cells for 2 h at 258C. Cells were harvested and lysed by sonication in PBS and debris removed by centrifugation. One ml of Talon matrix (Clontech, Palo Alto, CA) was incubated with the supernatant for 30 min and the beads collected and washed with TEN buer (20 mM Tris-HCl, 50 mM NaCl, pH 8.0). ELF3 was eluted from the beads in TEN buer supplemented with 100 mM imidazole. Analysis of the preparation by standard denaturing SDS-polyacrylamide gel electrophoresis revealed that the preparation contained approximately 90% monomer ELF3, having the expected molecular weight of 42 kD.
Recombinant ETS1 and ELF1 were produced by transient transfection of the respective expression vectors into COS cells. Sub-con¯uent cells were trypsinized, washed in growth medium and resuspended in PBS with 20 mM HEPES at 5610 6 cells/ml. 300 ml of cells were mixed with 20 mg DNA in 0.4 cm gap electroporation cuvettes and pulsed at 170 V and 500 mF (Biorad Gene Pulsar). Cells were re-plated into 10 cm petri dishes and harvested 24 h later. Nuclear lysates from COS cells were prepared as previously described (Thomas et al., 1995) . DNA binding experiments with nuclear lysates were performed using EMSA, as previously described (Thomas et al., 1995) . Brie¯y, puri®ed double stranded oligonucleotides were labeled with a-32 P-dATP by Klenow ®ll-in reaction. 10 ng oligonucleotide probe was incubated for 10 min with approximately 0.1 mg puri®ed ELF3 protein or 2 mg COS nuclear extract in DNA binding buer (1 mM EDTA, 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 5 mM MgCl 2 , 3 mM dithiothreitol (DTT), 1 mg/ml BSA, 500 ng/ml poly-d(I-C).d(I-C), 500 ng/ml poly dI-dC, 200 ng/ml sheared salmon sperm DNA),+1 mg/3 mg unlabeled competitor oligonucleotides, in 10 ml ®nal volume. Assays were run through nondenaturing, 7% acrylamide (29 acrylamide:1 bis-acrylamide), 0.56TBE gels at 48C.
Oligonucleotide sequences used (shown in double stranded conformation):
Transfection of COS cells and chloramphenicol acetyltransferase (CAT) assays COS7 cells were transfected with 5 mg CAT reporter plasmid and 10 mg of expression constructs by electroporation, as described above. Cells were harvested 48 h later and processed for CAT assays as previously described (Thomas et al., 1995) . All raw CAT data was normalized to the expression of p5XpolyTK, which was given the value of 100'. The mean and standard error of the mean (s.e.m.) were generated from four replicates of each experiment. Data was subject to statistical analysis using unpaired twotailed t-tests, with resultant P values less than 0.05 considered signi®cant.
Isolation and characterization of full-length human and murine ELF3/Elf3 cDNAs An EST from prostate cDNA library was used to screen a fetal lung cDNA library (Clontech HL3022b). A number of cDNA clones were obtained but none encoded the fulllength transcript. Additional 5-prime sequence was obtained by RT ± PCR using a Marathon cDNA synthesis kit (Clontech) and RACE (Rapid Ampli®cation of cDNA Ends) using human fetal lung RNA. The murine Elf3 cDNA was isolated from an adult lung cDNA library in Lambda ZAPII (Clontech). Additional 5-prime sequence was obtained by RACE using murine adult lung RNA (see below). All cDNA sequences were con®rmed by sequencing both strands at least once.
Determination of the murine Elf3 transcriptional initiation site
An adapter-ligated cDNA library was made with 2 mg of murine adult lung poly(A) + RNA using a Marathon cDNA synthesis kit, according to the manufacturers instructions (Clontech). RACE ampli®cation was carried out using the supplied anchor primer AP1 together with the Elf3-speci®c primer P1 (5'-GGGTCAACAC-CAAGTCTTCAGTGCCAA-3') close to the 5' end of the cDNA. A second round of ampli®cation was then carried out using the nested anchor primer AP2 and the nested Elf3 primer P2 (5'-GCTGTACATGGCGTTGAAG-TAGTTAC-3'). PCR products were analysed on a 2.0% agarose gel, Southern blotted and probed with a 1.6 kb murine Elf3 cDNA which contained the poly(A) + tail (obtained from library screening). The Elf3-speci®c PCR product was cloned into pGEM-T vector (Promega Corp., Madison, WI) and DNA sequencing carried out.
Isolation and characterization of the full murine Elf3 genomic sequence
Genomic DNA clones were isolated by screening a murine 129SVJ library in the lambda FIXII vector (Stratagene). Genomic sequences were subcloned for sequencing by either direct subcloning of restriction fragments into appropriate plasmid vectors or by cloning of PCRgenerated fragments into pGEM-T plasmid vector. PCR reactions were performed in a Perkin Elmer 9600 thermocycler with 1mL of phage stock in reaction buer containing 1.5 mM MgCl 2 and 0.2 U/mL Taq DNA polymerase (Boehringer Mannheim, Indianapolis, IN) with a 30 cycle ampli®cation of 948C (30 s), 508C (30 s), 728C (from 1 ± 8 min).
FISH
Human chromosomal localization by FISH was as previously described (Callen et al., 1990) . A 900 bp ELF3 cDNA probe was nick translated with biotin-14 -dATP and hybridized independently to metaphases from two normal males.
STS content mapping
PCR primers speci®c for ELF3 were designed with the computer program Primer v0.5. The 5' nucleotide for the forward (5'-CTCCAGCACCTTCTTTCTGG-3') and reverse (5'-TGGAACAGTCCAGCACTCTG-3') primers were 1622 and 1803, respectively. The PCR reactions were performed in standard buer (10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl) with 25 ng of genomic template DNA, 1 mM of each primer, 200 mM of each dNTP and 0.25 U of Taq DNA polymerase in a total volume of 10 mL. PCR parameters were an initial denaturation step at 948C for 2 min, followed by 35 cycles of 948C (30 s), 558C (30 s), 728C (30 s). For PCR experiments with the Coriell Mapping Panel 2 (Coriell Institute, Camden NJ), the DNA from the 24 monochromosome hybrids were pooled as described in Figure  4b in order to reduce the number of reactions. For PCR experiments with the Genebridge 4 and Stanford G3 Radiation Hybrid Panels (Research Genetics; Huntsville, AL), reactions were performed separately for each of the individual hybrids. The PCR results from the 93 hybrids for the Genebridge 4 panel were submitted to the Radiation Hybrid Mapper server at Whitehead Institute/ MIT Center for Genome Research (http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl). The PCR results from the 82 hybrids for the Stanford G3 panel were submitted to the Radiation Hybrid Mapper server at the Stanford Human Genome Center (rhserver@toolkit.Stanford,edu). All STS content mapping experiments were performed in duplicate and included PCR reactions with no DNA, total human DNA and total mouse DNA as controls.
RNase protection analysis ELF3 mRNA abundance in total RNA from human tissues and cell lines was determined as described previously (Tymms, 1995) . Antisense RNA probes for human ELF3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcribed from linearized plasmid vectors generated full-length probes of 451 bp and 216 bp respectively. The protected products generated by hybridization and RNase digestion are 373 bp for ELF3 and 160 bp for GAPDH.
Northern analysis
Northern analysis of ELF3 expression in human adult organs was performed with commercially available blots containing 2 mg of poly(A) + RNA (Clontech). For other Northern blots poly(A) + RNA was isolated by a modifiction of Gonda et al. (1992) . Random-primed probes using a 700 bp BamHI-BglII human ELF3 cDNA fragment and a 1.6 kb murine Elf3 fragment containing the poly(A) + tail (obtained from cDNA library screening) were generated and hybridizations performed using standard procedures. Blots were reprobed with GAPDH cDNA to verify RNA loading.
Note added in proof After this manuscript was submitted a manuscript describing the human ELF3 cDNA appeared (Chang et al, Oncogene, 14, 1617 ± 1622 with the gene name ESX.
